Trials
2 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Vitiligo, Non-Segmental Vitiligo (NSV), Alopecia Areata
- Main trialPhase 2
- “The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.”In the company’s words, NCT07533019 on ClinicalTrials.gov
Other drugs for Vitiligo
- RitlecitinibPfizer · Phase 3
- MH004Minghui Pharmaceutical (Hangzhou) Ltd · Phase 3
- UpadacitinibAbbVie · Phase 3
- TEV-53408Teva Branded Pharmaceutical Products R&D LLC · Phase 2/3
- Afamelanotide and NB-UVB LightClinuvel, Inc. · Phase 3
- D-2570InventisBio Co., Ltd · Phase 2
Coming up2
- May 2027Phase 2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | May 2027 | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | |
| Phase 2Recruiting | Jun 2027 | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | |
| Phase 1Completed | 28 Apr 2026 | A Study of LY4005130 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026